Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genzyme | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Genzyme

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme

3Q Revenues: $808.6 million (+14%)

3Q Earnings: $16 million (earnings were $115.7 million 3Q2005)*

YTD Revenues: $2.3 billion (+16%)

YTD Earnings: $251 million (-25%)

Comments: Myozyme was a significant new contributor in the quarter with the first full quarter of sales $20.4 million. Fabrazyme, Aldurazyme, Cerezyme and Renagel also contributed to revenue growth in the quarter. Sales of Fabrazyme rose 18% to $93.2 million. Sales of Aldurazyme rose 24% to $25 million. Sales of Cerezyme were $252.2 million, up 6%. Renagel sales were up 26% to $134.7 million in the quarter.

*Earnings for the quarter include a charge of $149.4 million for the impairment of goodwill associated with the company’s genetic testing business; an amortization expense of $31.9 million; and a stock compensation expense of $30.3 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters